echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Genxi biology announces fast car-t, a breakthrough technology for hematological malignancies

    Genxi biology announces fast car-t, a breakthrough technology for hematological malignancies

    • Last Update: 2019-04-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    April 23, 2019 / Meitong news agency / -- Genxi Biotechnology Group Co., Ltd ("Genxi biology"), an immune cell gene drug research and development company, announced that it has developed a revolutionary fastcar-t production platform This technology can shorten the manufacturing time of car-t from two weeks to one day Compared with the traditional car-t therapy (c-car-t), fastcar-t greatly reduces the manufacturing cost At the same time, in vivo and in vitro studies show that CD19 directed fastcar-t ("cd19-f-car-t") has a higher therapeutic effect on B-ALL and NHL Genxi biology is currently carrying out the first human clinical study of fastcar-t, the company said, the preliminary results show that the treatment is safe and significantly more effective than c-car-t preparation, and its effective dose for B-cell acute lymphoblastic leukemia (B-ALL) is only 20-40 times of c-car-t Genxi biology presented the excellent results of fastcar-t's first human study at the global car-t cell therapy development forum held in Shanghai from April 16 to 17, 2019 Fastcar-t only needs 1 day of production time (but according to regulatory requirements, quality release test needs 7 days), while c-car-t generally needs about two weeks of production time, plus 7 days of test time, so fastcar-t can be delivered back to patients about 12 days in advance This is critical for patients who are progressing rapidly What's more, Gemini showed that cd19-f-car-t had more young and less depleted phenotypes, and showed strong amplification ability Dr Cao Wei, founder, chairman and chief executive officer of Genxi biology, said: "car-t products have long manufacturing time, high cost, easy recurrence and invalid solid tumor, which are the main challenges facing car-t industry The mission of Gemini is to provide efficient and low-cost immune cell genetic drugs for cancer patients Without the support of patients, their families and clinical scientists, we cannot develop the promising fastcar-t technology into a product " Genxi biology has successfully completed the development of a series of efficient and low-cost car-t products In addition to fastcar-t platform, the company has also completed pre clinical development of double chimeric antigen receptor car-t products, ready to use car-t products, and enhanced car-t products for the treatment of refractory solid tumors Two products will apply for ind at the end of this year, and three products will apply for ind next year Genxi biology, led by Dr Cao Wei, was founded in 2017 Dr Cao was the co-founder and CEO of NASDAQ listed cell therapy company Since its establishment, the company has completed nearly $100 million of financing, including investment led by Temasek, b-round investment jointly funded by Lilly Asia ventures, Kington capital, King Star capital and Chengdu Miaoji, and a-round investment by Tonghe Yucheng About gracell bio, founded in 2017, is headquartered in Suzhou, China, with R & D centers and offices in Shanghai and Hong Kong Genxi biology is committed to solving the main challenges of cell gene therapy industry, including high production cost, long manufacturing process, lack of ready to use products, and short duration of treatment effect Gemini's mission is to provide cancer patients with the best and affordable cell genetic drugs Source: Genxi biotechnology group
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.